secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2024-01-05T23:59:59+00:00
Accession:  0001628280-24-000524
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine appoints Allan Reine as CFO, effective Jan 17, 2024
------------------------------------------------------------------

- Allan Reine named CFO and principal financial officer; previously CFO of Foghorn Therapeutics.
- Receives $500k base salary, $176k sign-on bonus, 40% target annual bonus, and option grants (600k time-vesting shares + 250k milestone-based shares).
- Carman Alenson transitions from interim CFO to SVP Finance and CAO; remains principal accounting officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024000524/0001628280-24-000524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000162828024000524/prme-20240104.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-000524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer